BOSTON SCIENTIFIC CORP (BSX) Stock Price, Forecast & Analysis
USA - NYSE:BSX - US1011371077 - Common Stock
BSX Key Statistics, Chart & Performance
The current stock price of BSX is 99.93 USD. In the past month the price increased by 1.82%. In the past year, price increased by 12.24%.
BSX Latest News, Press Relases and Analysis
BSX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.22 | 219.05B | ||
| ISRG | INTUITIVE SURGICAL INC | 64.78 | 199.95B | ||
| SYK | STRYKER CORP | 27.02 | 136.06B | ||
| IDXX | IDEXX LABORATORIES INC | 55.86 | 56.35B | ||
| BDX | BECTON DICKINSON AND CO | 12.18 | 50.35B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.35 | 48.81B | ||
| RMD | RESMED INC | 25.24 | 36.47B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.93 | 33.39B | ||
| PODD | INSULET CORP | 75.29 | 22.42B | ||
| DXCM | DEXCOM INC | 29.39 | 21.44B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.96 | 17.57B | ||
| HOLX | HOLOGIC INC | 17.36 | 16.49B |
Related stock screener links
About BSX
Company Profile
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Company Info
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS 01752 US
CEO: Michael F. Mahoney
Employees: 53000
Phone: 15086834000
BOSTON SCIENTIFIC CORP / BSX FAQ
What does BOSTON SCIENTIFIC CORP do?
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
What is the stock price of BOSTON SCIENTIFIC CORP today?
The current stock price of BSX is 99.93 USD. The price increased by 0.89% in the last trading session.
Does BOSTON SCIENTIFIC CORP pay dividends?
BSX does not pay a dividend.
How is the ChartMill rating for BOSTON SCIENTIFIC CORP?
BSX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is BOSTON SCIENTIFIC CORP (BSX) stock traded?
BSX stock is listed on the New York Stock Exchange, Inc. exchange.
What do analysts say about BOSTON SCIENTIFIC CORP (BSX) stock?
41 analysts have analysed BSX and the average price target is 127.97 USD. This implies a price increase of 28.06% is expected in the next year compared to the current price of 99.93.
Is BOSTON SCIENTIFIC CORP (BSX) expected to grow?
The Revenue of BOSTON SCIENTIFIC CORP (BSX) is expected to grow by 19.72% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
BSX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to BSX. When comparing the yearly performance of all stocks, BSX turns out to be only a medium performer in the overall market: it outperformed 59.59% of all stocks.
BSX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BSX. While BSX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
BSX Financial Highlights
Over the last trailing twelve months BSX reported a non-GAAP Earnings per Share(EPS) of 2.95. The EPS increased by 25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.54% | ||
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| Debt/Equity | 0.5 |
BSX Forecast & Estimates
41 analysts have analysed BSX and the average price target is 127.97 USD. This implies a price increase of 28.06% is expected in the next year compared to the current price of 99.93.
For the next year, analysts expect an EPS growth of 20.01% and a revenue growth 19.72% for BSX